Institute for Antiviral Research, Utah State University, Logan, 84322-5600, United States.
Antiviral Res. 2013 Feb;97(2):169-79. doi: 10.1016/j.antiviral.2012.12.002. Epub 2012 Dec 10.
A number of viruses in the family Flaviviridae are the focus of efforts to develop effective antiviral therapies. Success has been achieved with inhibitors for the treatment of hepatitis C, and there is interest in clinical trials of drugs against dengue fever. Antiviral therapies have also been evaluated in patients with Japanese encephalitis and West Nile encephalitis. However, no treatment has been developed against the prototype flavivirus, yellow fever virus (YFV). Despite the availability of the live, attenuated 17D vaccine, thousands of cases of YF continue to occur each year in Africa and South America, with a significant mortality rate. In addition, a small number of vaccinees develop severe systemic infections with the 17D virus. This paper reviews current efforts to develop antiviral therapies, either directly targeting the virus or blocking detrimental host responses to infection.
有许多黄病毒科的病毒是开发有效抗病毒疗法的重点。针对丙型肝炎的抑制剂已取得成功，并且对治疗登革热的药物临床试验也很感兴趣。抗病毒疗法也已在患有日本脑炎和西尼罗河脑炎的患者中进行了评估。但是，针对原型黄病毒，即黄热病病毒（YFV），尚无治疗方法。尽管有减毒活疫苗 17D 可用，但每年在非洲和南美洲仍有数千例黄热病病例发生，死亡率很高。此外，少数疫苗接种者会发生严重的全身感染 17D 病毒。本文综述了目前开发抗病毒疗法的努力，这些疗法要么直接针对病毒，要么阻止宿主对感染的有害反应。
